Omega-3 can kill cancer cells, says study

13 April 2009

Docosahexanoic acid (DHA), an omega-3 fatty acid, has been shown to reduce the size of tumors and enhance the positive effects of the  chemotherapy drug cisplatin, while limiting its harmful side effects,  according to the open-access journal Cell Division.

A El-Mowafy led a team of researchers from Mansoura University, Egypt,  who studied DHA's effects on solid tumors growing in mice, as well as  investigating how this fatty acid interacts with cisplatin, a  chemotherapy drug that is known to cause kidney damage. He said: "DHA  elicited prominent chemopreventive effects on its own, and appreciably  augmented those of cisplatin as well. Furthermore, this study is the  first to reveal that DHA can obliterate lethal cisplatin-induced  nephrotoxicity and renal tissue injury."

The researchers found that, at the molecular level, DHA acts by reducing  leukocytosis, systemic inflammation and oxidative stress - all processes  that have been linked with tumor growth.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight